Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022

Rhea-AI Summary

Kezar Life Sciences (KZR) announced the presentation of three posters at the American College of Rheumatology (ACR) Convergence 2022 from November 10-14 in Philadelphia, PA. The key presentation will feature full data from the Phase 2 MISSION study, where all 17 patients completed a 37-week trial of Zetomipzomib (KZR-616). Additional findings will be shared that are not included in the abstract. The presentations will cover topics like health-related quality of life in lupus nephritis patients and healthcare cost management.

Positive

• Successful completion of the Phase 2 MISSION study with all 17 patients completing the trial.
• Presentation of valuable data at a prominent conference, likely increasing visibility and interest in Zetomipzomib.

Negative

• None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2022, which will take place November 10 – 14, 2022 in Philadelphia, PA. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation that are not available in the abstract.

Poster Presentation Details:

Abstract Title: Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Session: SLE – Treatment Poster II
Date/Time: November 13, 2022 from 9:00 AM - 10:30 AM ET
Presenter: Amit Saxena, MD, Assistant Professor, NYU School of Medicine

Abstract Title: Poor Health-Related Quality of Life in Patients with Lupus Nephritis
Session: Patient Outcomes, Preferences, and Attitudes Poster II
Date/Time: November 13, 2022 from 1:00 PM - 3:00 PM ET
Presenter: Cristina Arriens, MD, Clinical Associate Member, Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation

Abstract Title: Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Poster Session: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More
Date/Time: November 12, 2022 from 1:00 PM - 3:00 PM ET
Presenter: Kenneth Kalunian, MD, Professor of Medicine, University of California San Diego

The accepted ACR abstracts are currently available on the congress platform here. Following the conference, the presentation materials will be available in the “Scientific Publications” section of Kezar Life Science’s website at www.kezarlifesciences.com.

About Zetomipzomib (KZR-616)

Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1 clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005862/en/

Investor Contact:

Gitanjali Jain

Vice President, Investor Relations and External Affairs

gjain@kezarbio.com



Media Contact:

Julia Deutsch

Solebury Strategic Communications

jdeutsch@soleburystrat.com

Source: Kezar Life Sciences, Inc.

FAQ

What are the key findings from Kezar Life Sciences' Phase 2 MISSION study?

The full data set from the Phase 2 MISSION study will be presented, highlighting the results of all 17 evaluable patients who completed the 37-week trial.

When and where will the ACR Convergence 2022 take place?

The ACR Convergence 2022 will be held from November 10 to 14, 2022, in Philadelphia, PA.

What is Zetomipzomib (KZR-616) and its significance in the KZR portfolio?

Zetomipzomib is a first-in-class selective immunoproteasome inhibitor being evaluated for the treatment of lupus nephritis, showcasing potential across various autoimmune diseases.

How does the ACR presentation impact KZR's market potential?

Presenting at ACR raises awareness and credibility for KZR's treatments, which could enhance market interest and investment in the company.